Clinical Advances in the Management of Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) , which affects approximately 250,000 people in the United States, is an autoimmune disorder characterized by multisystem inflammation due to autoantibodies. This chronic disease can affect any organ system, but mainly involves the skin, joints, kidneys, blood cells, and nervous system. It has a variable clinical course; treatment is evolving and depends on disease severity and manifestations. This collection was developed to help clinicians stay abreast of the latest advances in the management of this complex disorder.

Recent Updates in SLE CME/CE
Drs Daniel Wallace, Joan Merrill, Michelle Petri, and Gregg Silverman discuss the latest advances in SLE.

December 21, 2012

The Many Faces of SLE: Exploring 2 Challenging Cases CME/CE
Explore these cases of patients with SLE, one with lupus nephritis and the other with arthritis.
November 30, 2012
Management Challenges and Novel Advances in Systemic Lupus Erythematosus CME/CE
Join Drs Petri, Buyon, Merrill, and Rovin for a lively discussion on the major challenges in SLE management.
October 22, 2012
Lupus Management: Strategies for Monitoring Disease Activity and Treatment Outcomes CME/CE
Dr Richard Furie examines the use of disease activity measurements in SLE.
September 21, 2012
Latest Advances in SLE From the Berlin 2012 Meeting CME/CE
Drs Wallace, Isenberg, Merrill, and Petri discuss highlights on SLE from the Berlin 2012 meeting.
June 19, 2012
Improving the Management of Systemic Lupus Erythematosus: A Clinical Practice Assessment CME
How do you treat patients with SLE, and what are the barriers to treatment that you face?
May 31, 2012

Steering Committee Chair

Michelle Petri, MD, MPH
Professor
Department of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Participation by Dr. Petri as a member of the Scientific Advisory Board does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Steering Committee Members

Richard A. Furie, MD
Director, The Systemic Lupus Erythematosus and Autoimmune
Disease Treatment Center;
Director, The Program in Novel
Therapeutics; Chief, Division of
Rheumatology and Allergy-Clinical
Immunology, North Shore-Long Island Jewish Health System, New Hyde Park, NY
Joan T. Merrill, MD
Oklahoma Medical Research Foundation Professor of Medicine,
University of Oklahoma Health Sciences Center; Head, Clinical
Pharmacology Research Program,
Oklahoma Medical Research
Foundation, Oklahoma City, Oklahoma

Gregg J. Silverman, MD
Professor of Medicine and Pathology;
Co-Director, Musculoskeletal
Center of Excellence,
Division of Rheumatology,
NYU Langone Medical Center,
New York, NY

Daniel J. Wallace, MD
Clinical Professor of Medicine,
David Geffen School of Medicine at
UCLA; Attending Physician,
Cedars Sinai Medical Center,
Los Angeles, California

Supported by an independent educational grant from
Human Genome Services

Downloadable Slide Kit

Systemic Lupus Erythematosus: An Update
This downloadable slide deck provides an overview of the etiology, classification, and current treatment options for systemic lupus erythematosus.

Clinical Articles

Steering Committee

Michelle Petri, MD, MPH

Disclosure: Michelle Petri, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for Anthera Pharmaceuticals; Genentech, Inc.; GlaxoSmithKline; Human Genome Sciences, Inc.; MedImmune, Inc.; Pfizer, Inc; UCB S.A.
Received grants for clinical research from: MedImmune, Inc.; GlaxoSmithKline

Richard A. Furie, MD

Disclosure: Richard A. Furie, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Anthera Pharmaceuticals; Argos Therapeutics; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Biogen Idec Inc.; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Exagen Diagnostics, Inc.; Genentech, Inc.; GlaxoSmithKline; Human Genome Sciences, Inc.; Idera Pharmaceuticals Inc.; MedImmune Inc.; Merck & Co., Inc.; Nimbus Pharma; Novo Nordisk; Questcor Pharmaceuticals, Inc.; Remmunix Ltd.; Rigel; UCB Pharma, Inc.
Served as a speaker or member of a speakers bureau for: GlaxoSmithKline; Human Genome Sciences, Inc.
Received grants for clinical research from: Argos Therapeutics; Astellas Pharma, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Human Genome Sciences, Inc.; MedImmune Inc.; Novo Nordisk; Rigel; UCB Pharma, Inc.
Owns stock, stock options, or bonds from: Pfizer Inc.

Joan T. Merrill, MD

Disclosure: Joan T. Merrill, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Amgen Inc.; Argos Therapeutics; Astellas Pharma, Inc.; Baxter; Cephalon, Inc.; Eisai, Inc.; EMD Serono, Inc.; Genentech, Inc.; GlaxoSmithKline; Human Genome Sciences, Inc.; Lilly USA, LLC; MedImmune Inc.; Ono Pharmaceutical Co., Ltd.; PAREXEL International; Pfizer Inc; Questcor Pharmaceuticals, Inc.; Roche; Research Pharmaceutical Services, Inc.; Takeda Pharmaceuticals North America, Inc.; UCB S.A.
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Bristol-Myers Squibb; GlaxoSmithKline; Human Genome Sciences; Lilly USA, LLC; Pfizer Inc, Research Pharmaceutical Services, Inc.; UCB S.A.
Received grants for clinical research from: Bristol-Myers Squibb Company; Genentech, Inc.; Pfizer Inc; Roche; UCB S.A.
Served on the data and safety monitoring board for: Amgen Inc.; Celgene Corporation; Pfizer Inc

Gregg J. Silverman, MD

Disclosure: Gregg J. Silverman, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche; MedImmune Inc., Genentech, Inc.; Biogen Idec, Inc.
Served as a speaker or a member of a speakers bureau for: Genentech, Inc.

Daniel J. Wallace, MD

Disclosure: Daniel J. Wallace, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Dynavax Technologies Corporation; GlaxoSmithKline; Human Genome Sciences, Inc.; Pfizer Inc; Teva Pharmaceutical Industries Ltd; UCB S.A.
Served as a speaker or a member of a speakers bureau for: GlaxoSmithKline; Human Genome Sciences, Inc.

	What is the most common age for first presentation of your patients with SLE?
		Teenage years
		20s to 30s
		40s to 50s
		60s or older